Aurobindo Pharma Share Price (AUROPHARMA)
as on
| Source : NSE
🔔 Acquisition Alert
Aurobindo Pharma clarifies no binding agreement for $5-5.5 billion acquisition of Zentiva; reports deemed premature.
Aurobindo Pharma Stock Performance
as on August 20, 2025 at 2:56 PM IST
Day's Low
Day's High
₹1,039₹1,078
0.69%
Downside
3.04%
Upside
52 Week's Low
52 Week's High
₹1,010₹1,5923.46%
Downside
52.17%
Upside
| Market Stats | |
| Previous Close | ₹1,089.70 |
| Open | ₹1,046.00 |
| Volume | 41.73L |
| Upper Circuit | ₹1,198.60 |
| Lower Circuit | ₹980.80 |
| Day's Low | ₹1,039 |
| Day's High | ₹1,078 |
| 52 Week Low | ₹1,010 |
| 52 Week High | ₹1,592 |
| Returns % | |
| 1 Month Return | -4.29 % |
| 3 Month Return | -8.57 % |
| 1 Year Return | -29.12 % |
| 3 Year Return | + 97.5 % |
| 5 Year Return | + 27.08 % |
Aurobindo Pharma Stock Fundamentals & Key Indicators
Check Aurobindo Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹63,849.73 Cr
Return on Equity (ROE)
8.68
PE Ratio (TTM)
18.68
Return on capital employed (ROCE)
10.82
Industry PE ratio
43.53
Beta (LTM)
0.96
P/B Ratio
0Dividend Yield
0PEG Ratio
-10.68
Quarterly Earnings Growth YOY
-10.24
EPS (TTM)
59.98
Sector
Pharmaceuticals
Book Value
562.21
Technical Analysis
Bearish
View Technical Analysis
Aurobindo Pharma Stock's Interest Amongst Investors
Aurobindo Pharma Stock Valuation
Track how Aurobindo Pharma P/E has moved over time to understand its valuation trends.
Aurobindo Pharma in the last 5 years
Lowest (6.73x)
March 23, 2020
Today (18.68x)
August 19, 2025
Industry (43.53x)
August 19, 2025
Highest (27.59x)
December 21, 2023
Today’s Price to Earnings Ratio: 18.68x
Aurobindo Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Aurobindo Pharma.
based on 28 analysts
82.14%
Buy
0.00%
Hold
17.86%
Sell
82.14% of analysts recommend a 'BUY' rating for Aurobindo Pharma. Average target price of ₹1293.39
Source: S&P Global Market Intelligence
Aurobindo Pharma Share Price Target
Get share price movements and forecasts by analysts on Aurobindo Pharma.
Aurobindo Pharma price forecast by 28 analysts
Upside of18.69%
High
₹1930
Target
₹1293.39
Low
₹730
Aurobindo Pharma target price ₹1293.39, a slight upside of 18.69% compared to current price of ₹1046.2. According to 28 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Aurobindo Pharma revenue growth forecast
Expected growth rate Q1, FY2027:15.84%
Forecast
Actual
Including amortisation and stock based compensations
Aurobindo Pharma EPS growth forecast
EPS estimate Q1, FY2027:25.41%
Forecast
Actual
Source: S&P Global Market Intelligence
Aurobindo Pharma Ltd Financial Results
Get the annual and quarterly financial summary of Aurobindo Pharma Ltd, including revenue, profit, loss and more.
Aurobindo Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Aurobindo Pharma.
Aurobindo Pharma Ltd Earnings Results
Aurobindo Pharma Ltd’s net profit fell -10.28% since last year same period to ₹824.75Cr in the Q1 2025-2026. On a quarterly growth basis, Aurobindo Pharma Ltd has generated -8.71% fall in its net profits since last 3-months.
Read More about Earnings ResultsAurobindo Pharma Ltd Dividends August,2025
In the quarter ending June 2025, Aurobindo Pharma Ltd has declared dividend of ₹4.00 per share on 04 Aug 2025 - translating a dividend yield of 0.37%.
Read More about Dividends
Indices Featuring Aurobindo Pharma Stock
Check stock indices that include Aurobindo Pharma.
Aurobindo Pharma Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Aurobindo Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.82% | 0.00 | |
| Foreign Institutions | 14.37% | ||
| Mutual Funds | 18.96% | 4.14 | |
| Retail Investors | 6.87% | 3.92 | |
| Others | 7.97% |
Aurobindo Pharma Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Aurobindo Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| BUY | 63,849.73 | 5.42% | 0.60 | 3,483 | 31,723 | |
| BUY | 11,915.72 | -7.7% | 0.52 | 413 | 2,013 | |
| HOLD | 99,561.82 | 29.66% | 0.61 | 4,614 | 23,241 | |
| BUY | 70,263.13 | 19.2% | 0.00 | 1,414 | 6,445 | |
| BUY | 47,555.66 | 17.68% | 0.56 | 927 | 3,749 |
Aurobindo Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Aurobindo Pharma.
Aurobindo Pharma's Zentiva Acquisition News Causes Stock Volatility - 20 Aug, 2025
Aurobindo Pharma's shares experienced volatility due to reports of a potential $5-5.5 billion acquisition of Zentiva. The company clarified that no binding agreement exists, emphasizing ongoing strategic evaluations. Despite initial declines, shares showed slight recovery after the clarification.Aurobindo Pharma Targets Break-Even in China by FY26 - 17 Aug, 2025
Aurobindo Pharma anticipates its China facility will break even by Q3 FY26, supported by $145 million investment. Despite a 10% dip in net profit, the company remains optimistic about growth and margin targets.Aurobindo Pharma Sees Modest Gains Amidst Decline - 13 Aug, 2025
Aurobindo Pharma Ltd rose 1.82% today, marking its third consecutive session of gains. However, the stock has declined 5.37% over the past month and 29.1% over the last year, underperforming compared to the NIFTY and Nifty Pharma index.Citi Highlights Setback for Aurobindo Pharma - 12 Aug, 2025
Aurobindo Pharma faces potential setbacks as Citi reports USFDA approvals for competitors' generic Iron Sucrose, diminishing Aurobindo's market opportunity. The company will also participate in a virtual investor conference.Aurobindo Pharma Faces Tariff Pressure, Declares Dividend - 07 Aug, 2025
Aurobindo Pharma's shares dropped due to new US tariffs. The company announced a ₹4 interim dividend and received a BUY upgrade from ICICI Securities with a target of ₹1,300.Brokerages Maintain Buy Ratings Amid Mixed Outlook - 06 Aug, 2025
Aurobindo Pharma faces mixed brokerage reactions post Q1 FY26 results. While maintaining Buy ratings, brokerages express concerns over US sales and margin pressures, but highlight growth in EU and ARV segments.Aurobindo Pharma Reports Weak Q1 Results, Shares Decline - 05 Aug, 2025
Aurobindo Pharma reported a 10.3% drop in net profit for Q1 FY26, missing estimates. Macquarie downgraded the stock, citing concerns over US market growth. Shares fell over 2% following the results.Aurobindo Reports Profit Decline but Declares Dividend - 04 Aug, 2025
Aurobindo Pharma announced a ₹4 interim dividend despite a 10.3% decline in Q1 FY26 net profit to ₹824.2 crore. Revenue grew 4% but missed estimates. Shares rose 1.04% following the announcement.Aurobindo Pharma Acquires Lannett Company for Growth - 30 Jul, 2025
Aurobindo Pharma's subsidiary, Aurobindo Pharma USA Inc., has entered a definitive agreement to acquire Lannett Company LLC for $250 million, aiming to expand its U.S. manufacturing footprint and diversify its product portfolio.
Insights on Aurobindo Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 6.61% to 6.87% in Jun 2025 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 18.21% to 18.96% in Jun 2025 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 51.82% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 139.2% return, outperforming this stock by 41.7%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 28.7% return, outperforming this stock by 57.8%
NEGATIVE IMPACTProfit Down
Netprofit is down for the last 2 quarters, 903.47 Cr → 824.75 Cr (in ₹), with an average decrease of 8.7% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 15.33% to 14.37% in Jun 2025 quarter
- NEGATIVE IMPACT
Price Dip
In the last 3 months, AUROPHARMA stock has moved down by -8.6%
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 8.51K Cr → 7.97K Cr (in ₹), with an average decrease of 6.4% per quarter
About Aurobindo Pharma Ltd
The company is well known for its top products such as antibiotics, anti-malarials, cardiovascular, and anti-diabetic drugs. Its popular brands include Aurolife, Aurocare, Aurochem, and Aurovit. Aurobindo Pharma is one of the largest manufacturers of generic drugs in India, with a presence in over 150 countries worldwide.
Revenue: ₹7,791.77Cr as on June 2025 (Q1 FY26)
Net Profit: ₹824.20Cr as on June 2025 (Q1 FY26)
Listing date: 19 Oct, 1995
Chairperson Name: K Ragunathan
| Organisation | Aurobindo Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | K Ragunathan |
| E-voting on shares | Click here to vote |
Mutual Funds that own Aurobindo Pharma Stock
Check out the Mutual Funds with significant holdings in Aurobindo Pharma.
FAQs
What is Aurobindo Pharma share price today?
Aurobindo Pharma share price today stands at ₹1046.2, Open: ₹1046, Previous Close: ₹1089.7, High: ₹1078, Low: ₹1039, 52 Week High: ₹1592, 52 Week Low: ₹1010 as on .
How to buy Aurobindo Pharma shares ?
To buy Aurobindo Pharma shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for AUROPHARMA or Aurobindo Pharma Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Aurobindo Pharma shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Aurobindo Pharma?
Today's traded volume of Aurobindo Pharma is 41.73L. Which means that 41.73L shares of Aurobindo Pharma were bought and sold on the stock market during today's trading session.
What is Aurobindo Pharma's market cap today?
Today's market capitalisation of Aurobindo Pharma is ₹63,849.73 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Aurobindo Pharma?
Aurobindo Pharma’s 52 week high is ₹1592 and 52 week low is ₹1010. The current share price of Aurobindo Pharma is ₹1046.2, which is -34.28% down from its 52 week high and 3.58% up from its 52 week low.